X. Wang, “Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis: Abiraterone versus enzalutamide in mCRPC”, J Pharm Pharm Sci, vol. 23, pp. 451–461, Nov. 2020.